These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 16248945)

  • 1. [Interferon-alpha and ribavirin combination therapy for co-infection of hepatitis C virus and human immunodeficiency virus].
    Zheng YH; He Y; Yang X; Gong GZ; Zhou HY; Zhang CY; Zhou W; Huang L; Ding PP; Li H
    Zhonghua Gan Zang Bing Za Zhi; 2005 Oct; 13(10):741-4. PubMed ID: 16248945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The preliminary efficacy of interferon-alpha and ribavirin combination treatment of chronic hepatitis C in HIV-infected patients.
    Zheng YH; Zhang CY; He Y; Zhou HY; Zou W; Ding PP; Huang L; Li H
    Chin Med J (Engl); 2005 Jul; 118(14):1195-200. PubMed ID: 16117865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.
    Sulkowski MS; Wasserman R; Brooks L; Ball L; Gish R
    J Viral Hepat; 2004 May; 11(3):243-50. PubMed ID: 15117326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribavirin in the treatment of hepatitis C.
    Abonyi ME; Lakatos PL
    Anticancer Res; 2005; 25(2B):1315-20. PubMed ID: 15865084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of chronic hepatitis C in patients with HIV infection].
    Begovac J
    Acta Med Croatica; 2005; 59(5):473-8. PubMed ID: 16381246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C.
    Laguno M; Blanch J; Murillas J; Blanco JL; León A; Lonca M; Larrousse M; Biglia A; Martinez E; García F; Miró JM; de Pablo J; Gatell JM; Mallolas J
    Antivir Ther; 2004 Dec; 9(6):905-9. PubMed ID: 15651749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
    Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
    Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.
    McHutchison JG; Shiffman ML; Cheung RC; Gordon SC; Wright TL; Pottage JC; McNair L; Ette E; Moseley S; Alam J
    Antivir Ther; 2005; 10(5):635-43. PubMed ID: 16152757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between plasma levels of eotaxin (CCL-11) and treatment response to interferon-alpha and ribavirin in HIV/HCV co-infected patients.
    Vargas A; Berenguer J; Catalán P; Miralles P; López JC; Cosín J; Resino S
    J Antimicrob Chemother; 2010 Feb; 65(2):303-6. PubMed ID: 20016018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hepatitis C virus infection in thalassemia.
    Butensky E; Pakbaz Z; Foote D; Walters MC; Vichinsky EP; Harmatz P
    Ann N Y Acad Sci; 2005; 1054():290-9. PubMed ID: 16339677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients.
    Guzmán-Fulgencio M; Jiménez JL; Berenguer J; Fernández-Rodríguez A; López JC; Cosín J; Miralles P; Micheloud D; Muñoz-Fernández MÁ; Resino S
    J Antimicrob Chemother; 2012 May; 67(5):1238-45. PubMed ID: 22294644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [An investigation of clinical features and immunological functions of HCV-specific cytotoxic T lymphocytes in HIV/HCV co-infected patients].
    DU XF; Zhang YH; Ma LN; Yan HP; Chen XY; Wu H
    Zhonghua Gan Zang Bing Za Zhi; 2008 May; 16(5):345-8. PubMed ID: 18510845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
    Bani-Sadr F; Lapidus N; Bedossa P; De Boever CM; Perronne C; Halfon P; Pol S; Carrat F; Cacoub P; ;
    Clin Infect Dis; 2008 Mar; 46(5):768-74. PubMed ID: 18248298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin.
    Bräu N; Rodriguez-Torres M; Prokupek D; Bonacini M; Giffen CA; Smith JJ; Frost KR; Kostman JR
    Hepatology; 2004 Apr; 39(4):989-98. PubMed ID: 15057903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of IL-2 on hepatitis C virus RNA levels in patients co-infected with human immunodeficiency virus receiving HAART.
    Tedaldi EM; Chen L; Markowitz N; Kelly L; Abrams D;
    J Viral Hepat; 2005 Jul; 12(4):414-20. PubMed ID: 15985013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection.
    Jain AB; Eghtesad B; Venkataramanan R; Fontes PA; Kashyap R; Dvorchik I; Shakil AO; Kingery L; Fung JJ
    Liver Transpl; 2002 Nov; 8(11):1007-13. PubMed ID: 12424713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological predictors of different responses to combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis C.
    Amaraa R; Mareckova H; Urbanek P; Fucikova T
    J Gastroenterol; 2003; 38(3):254-9. PubMed ID: 12673448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.
    Pockros PJ; Shiffman ML; Schiff ER; Sulkowski MS; Younossi Z; Dieterich DT; Wright TL; Mody SH; Tang KL; Goon BL; Bowers PJ; Leitz G; Afdhal NH;
    Hepatology; 2004 Dec; 40(6):1450-8. PubMed ID: 15565613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.